We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ip Group Plc | LSE:IPO | London | Ordinary Share | GB00B128J450 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.45 | 2.96% | 50.50 | 50.30 | 50.40 | 50.70 | 47.20 | 47.20 | 3,249,893 | 16:35:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -140.1M | -174.4M | -0.1682 | -2.99 | 521.57M |
From May 2019 to May 2024
By Jaime Llinares Taboada
IP Group PLC said Wednesday that its investee company Enterprise Therapeutics Ltd. has sold a portfolio of developing drugs for respiratory diseases to Roche Holding AG for an upfront payment of 75 million pounds ($96.6 million).
The developer of intellectual property-based businesses said Enterprise shareholders are also eligible to receive additional payments based on certain milestones. IP Group has a 21.7% beneficial shareholding in Enterprise.
The potentiator program portfolio that has been sold includes ETD002, which recently entered Phase 1 trials. This product is focused on treating cystic fibrosis, with potential to benefit people with other severe respiratory diseases.
IP Group said following the transaction, it has realized cash of GBP183.9 million so far this year, compared with GBP79.5 million in the whole 2019.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
October 07, 2020 03:21 ET (07:21 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Ip Chart |
1 Month Ip Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
